INTRODUCTION
The vitamin A metabolite retinoic acid (RA) regulates multiple biological processes and plays key roles in embryonic development and in tissue remodeling in the adult. It is well established that many of the activities of RA are mediated by retinoic acid receptors (RARa, b, and g), ligand-inducible transcription factors that are members of the superfamily of nuclear hormone receptors (Laudet and Gronemeyer, 2002) . RARs associate with the retinoid X receptor (RXR) to form heterodimers that bind to regulatory regions of specific target genes and modulate transcriptional rates in response to their cognate ligands (Chambon, 1996; Mangelsdorf et al., 1994) . Transcriptional activation by RAR may trigger differentiation (Park et al., 1999; Rochette-Egly and Chambon, 2001 ), cellcycle arrest (Donato et al., 2007) , and apoptosis (Altucci et al., 2001; Donato and Noy, 2005; Kitareewan et al., 2002) , and thus often leads to inhibition of cell proliferation. Accordingly, RA displays distinct anticarcinogenic activities and is currently used in or is being tested as a therapeutic agent in several human cancers (Soprano et al., 2004) .
However, in some tissues, RA appears to promote rather than inhibit cell survival. For example, RA is critical for neuronal survival (Henion and Weston, 1994; Jacobs et al., 2006; Plum et al., 2001; Rodriguez-Tebar and Rohrer, 1991) , and it was reported that RA treatment can enhance skin tumor formation (Verma et al., 1982) . RA is essential for normal keratinization in various epithelia (Wolbach and Howe, 1978) , and topical administration of the hormone stimulates dermal repair and induces hyperproliferation of basal kertinocytes (Kang et al., 1995; Zouboulis, 2001) . Interestingly, although RA plays critical roles in maintenance of skin integrity, mice lacking both RARa and RARg as well as RARb-null mice display normal keratinocyte proliferation (Chapellier et al., 2002) . These observations indicate that RARs are dispensable for keratinocyte renewal and suggest that some RA activities in the skin are mediated by an RAR-independent pathway.
We previously reported that RA binds with a high affinity to another nuclear receptor, namely PPARb/d, a member of a subclass of receptors, which also includes PPARa and PPARg, and that, like RAR, functions as a heterodimer with RXR (Laudet and Gronemeyer, 2002) . Selective association of RA with PPARb/d was suggested by the observations that the Kd for RA binding by this receptor is 15 nM, about an order of magnitude stronger than that displayed by PPARa and PPARg. Correspondingly, in the context of a reporter gene construct, RA was found to efficiently activate PPARb/d but not PPARa or PPARg (Shaw et al., 2003) . Hence, an intriguing possibility is that, in some cells, RA may activate transcription not only through RAR but also through PPARb/d. It is noteworthy in regard to this that, in keratinocytes, PPARb/d induces differentiation and, importantly, displays pronounced antiapoptotic activities mediated in part by direct transcriptional targeting of the PDK-1/Akt survival pathway (Di-Poi et al., 2002; Tan et al., 2004) . Consequently, PPARb/d is central to maintenance of skin permeability-barrier integrity and to keratinocyte survival during inflammation and wound healing (Di-Poi et al., 2003; Icre et al., 2006) .
Ligands that activate RAR and the various PPAR isotypes also bind in cells to intracellular lipid binding proteins (iLBPs), a family of small proteins that share a remarkably similar three-dimensional structure (Gutierrez-Gonzalez et al., 2002; Kleywegt et al., 1994; Veerkamp and Maatman, 1995) but bind lipophilic molecules with distinct selectivities. Some members of this family, termed cellular retinoic acid binding proteins (CRABP-I and II), specifically associate with retinoic acid with subnanomolar affinities (Dong et al., 1999) . Other iLBPs, known as fatty-acid binding proteins (FABPs), display broad selectivities and bind a variety of fatty acids and some fatty-acid derivatives. In fact, the spectrum of ligands that bind to FABPs is reminiscent of that of PPARs (Gutierrez-Gonzalez et al., 2002; Hanhoff et al., 2002; Norris and Spector, 2002; Widstrom et al., 2001) . The shared ligand selectivities of some iLBPs and some nuclear receptors suggest that specific members of the two classes of proteins may cooperate in regulating the biological activities of their common ligands. Such a cooperation is also suggested by overlapping tissue-expression profiles and by involvement in similar biological functions.
Recent studies indeed demonstrated that three iLBPs, CRABP-II, FABP5 (K-FABP, eFABP, mal1), and FABP4 (A-FABP, aP2), selectively cooperate with the nuclear receptors RARa, PPARb/d, and PPARg, respectively. Specifically, these studies established that, upon association with particular ligands, these binding proteins translocate from the cytosol to the nucleus, that they engage in direct protein-protein interactions with their ''cognate'' receptors, and that the resulting complex mediates ''ligandchanneling'' from the binding protein to the receptor. Consequently, the binding proteins facilitate the ligation of the respective receptors and significantly augment their transcriptional activities (Budhu and Noy, 2002; Dong et al., 1999; Manor et al., 2003; Sessler and Noy, 2005; Tan et al., 2002) . Interestingly, although FABP4 and FABP5 bind multiple ligands, only particular compounds trigger their nuclear translocation . FABP4 moves into the nucleus in response to ligands that activate PPARg but not upon treatment with PPARb/d ligands. In contrast, FABP5 mobilizes to the nucleus only in response to ligands that activate PPARb/d.
Hence, available information suggests the possibility that, while RA inhibits cell-growth by signaling through RAR, the ''nontraditional'' proproliferative activities of this hormone may be mediated by PPARb/d. Work described in this manuscript was undertaken in order to examine this hypothesis and to investigate the possibility that CRABP-II and FABP5 control the partitioning of RA between the two receptors.
RESULTS

RA Facilitates Tumor Growth in the MMTV-neu Transgenic Mammary Cancer Model
In keratinocytes, RA exerts proproliferative activities that appear to be mediated by a pathway other than activation of RAR (Chapellier et al., 2002) . In search for an additional model that will allow for exploring the mechanisms that underlie ''nontraditional'' activities of RA, we considered the transgenic mammary cancer mouse model TgN(MMTVneu)202Mul (Akagi et al., 1997; Guy et al., 1992) . The oncogenic hallmark of this model is a mammary-specific amplification of the growth-factor receptor c-erb-B2/neu, which is often amplified in primary human breast cancers (King et al., 1985) . This model, in which 100% of female mice develop mammary adenocarcinomas (Muller et al., 1988) , was chosen because it has been reported that overexpression of neu in mammary carcinoma cells leads to RA resistance, suggesting downregulation of RAR signaling (Tari et al., 2002) . To examine the effects of RA on tumor development, the rate of tumor growth was studied in untreated mice and in mice systemically treated with RA as of age 140 days. Measurements were initiated when tumors reached a volume of 0.065 cm 3 . The data ( Figure 1A) showed that RA treatment dramatically facilitated tumor formation with mean tumor volume on day 20 of 1.09 ± 0.22 cm 3 in untreated mice and 1.87 ± 0.25 cm 3 in the RA-treated group (mean ± S.E.M., n = 12 in each group, P = 0.04). Assessment of mouse survival, defined as the time when tumor volume reached 0.524 cm 3 ( Figure 1B ), indicated that, although all mice eventually developed tumors of that size, the median survival of RA-treated versus untreated mice was 205 versus 240 days (P = 0.001). Hence, RA exerts proproliferative activities in tumors that arise in MMTVneu mice.
Subsequent experiments thus utilized two cell lines in which RA displays ''nontraditional'' activities, leading to cell survival and growth: HaCaT keratinocyte cells and NaF cells, derived from tumors that arise in MMTVneu mice. For comparison, we employed MCF-7 mammary carcinoma cells, in which RA is known to function through RAR and to inhibit cell proliferation (Donato and Noy, 2005; Donato et al., 2007; Mangiarotti et al., 1998; Toma et al., 1998) .
In HaCaT Keratinocytes, RA Activates PPARb/d in Parallel to Activation of RAR The ability of RA to activate PPARb/d in the human keratinocyte cell line HaCaT was examined. Transcriptional activation assays conducted using a luciferase reporter driven by a consensus PPAR response element (PPRE) showed that the synthetic PPARb/d-selective ligand GW0742, but not the RAR-selective ligand 4-([E]-2- [5, 6, 7, 5, 8, -naphthalenyl]-1-propenyl)benzoic acid (TTNPB), induced transcription of the reporter (Figure 2A ). These observations attest to the expression and functionality of PPARb/d in these cells and demonstrate specificity of reporter response. RA also enhanced the expression of the PPRE-driven reporter and did so in a dose-responsive manner ( Figure 2B ). The response was markedly suppressed when the expression of PPARb/d in the cells was decreased by about 80% by siRNA methodology (Figure 2B ), indicating that the ability of RA to induce reporter expression was indeed mediated by this receptor and not by RAR.
We then set out to examine the ability of RA to induce the expression of endogenous PPARb/d target genes in HaCaT cells. One of these, PDK-1, was previously shown to comprise a direct PPARb/d target in HaCaT cells (Di-Poi et al., 2002) . Two other genes, fasting-induced adipose factor (FIAF) (Kersten et al., 2000) and adipose differentiation-related protein (ADRP) (Schmuth et al., 2004) , were reported to be targeted by PPARb/d in other cells. Chromatin immunoprecipitation assays demonstrated that PPARb/d associates with the PPAR response elements of both FIAF and ADRP in HaCaT cells ( Figure S1 ), verifying that both are direct targets for this receptor in the context of these cells. The PPARb/d ligand GW0742 as well as RA upregulated the expression of mRNA for all three of these endogenous PPARb/d target genes ( Figure 2C ). The observations that the RAR-ligand TTNPB had little effect on the expression of these genes further confirm that RAR is not involved in this activity of RA. As a control, cells were treated with 9-cis-RA (9cRA), a ligand that activates RXR, the obligatory heterodimerization partner for both RAR and PPARs (Levin et al., 1992) . This ligand induced a modest response, which likely emanated from activation of the RXR moiety of the RXR-PPARb/d heterodimer. The small magnitude of the response indicates that the induction of ADRP and FIAF by RA is not a result of conversion of RA to its 9-cis isomer within the cells. Further support for the conclusion that upregulation of these genes by RA is mediated by PPARb/d was provided by the observations that an 80% decrease in the expression of this receptor significantly hampered the induction of ADRP by both GW0747 and RA ( Figure 2D ).
Notably, one of the PPARb/d targets found to be induced by RA, PDK-1, is an important component of the antiapoptotic activities of this receptor in keratinocytes, where induction of this kinase leads to phosphorylation and activation of the downstream PDK-1-target survival factor Akt (Di-Poi et al., 2002) . The effects of RA or GW0742 on the phosphorylation level of Akt were thus examined. Treatment with either of these ligands, but not with TTNPB or 9cRA, significantly increased the phosphorylation level of Akt ( Figure 2E ).
In addition to activating PPARb/d, RA also upregulated the expression of a reporter gene construct driven by an RAR response element ( Figure 2F ), and it efficiently upregulated the expression of mRNA for CYP26a, a known direct RAR target gene (Loudig et al., 2000) ( Figure 2G ). Hence, in HaCaT cells, RA treatment results in parallel activation of both RAR and PPARb/d.
FABP5 Translocates into the Nucleus in Response to RA, and It Enhances RA-Induced, PPARb/d-Mediated Transcriptional Activation
The observations that RA can activate both RAR and PPARb/d raise the question of the factors that regulate the dual activity of this hormone. We previously showed that the iLBPs CRABP-II and FABP5 mobilize to the nucleus in response to ligands that activate RAR and PPARb/d, respectively, and that they bind to their cognate receptors to form a complex through which the ligand is directly ''channeled'' to the receptor. Consequently, CRABP-II enhances the transcriptional activity of RAR, while FABP5 facilitates the activation of PPARb/d (Budhu and Noy, 2002; Donato and Noy, 2005; Dong et al., 1999; Manor et al., 2003; Tan et al., 2002) . The observations that RA serves as a ligand for PPARb/d thus raise the possibility that RA may be delivered to this receptor by FABP5. A fluorescence-based binding assay (Figure 3A) demonstrated that GW0742 and RA bind to FABP5 with Kds of 42.3 ± 4.5 nM and 34.8 ± 6.6 nM, respectively (mean ± SD, n = 3), in good agreement with binding affinities of this protein toward other ligands . The subcellular localization of FABP5 was then examined. COS-7 cells were transfected with FABP5 fused to green fluorescence protein (GFP), and confocal fluorescence microscopy was used to image GFP-FABP5 in live cells treated with various ligands ( Figure 3B ). Similarly to the behavior of GFP when transfected alone, GFP-FABP5 in untreated cells distributed between the cytoplasm and the nucleus, most likely reflecting that overexpression of the protein leads to leakage into the nucleus even in the absence of a specific nuclear localization signal (data not shown and Sessler and Noy [2005] ). Treatment of cells with stearic acid, a long chain fatty acid that binds FABP5 but does not activate it, did not affect the subcellular distribution of the protein.
In contrast, treatment with either GW0742 or RA resulted in a distinct shift of the protein into the nucleus ( Figure 3B ). To monitor the effects of ligands on the localization of endogenous FABP5 in HaCaT cells, cells were treated with vehicle, RA, or stearate, subjected to subcellular fractionation, and the presence of FABP5 in cytosol and in nuclei examined by immunoblots ( Figure 3C ). The data demonstrated that endogenous FABP5 in HaCaT cells is predominantly cytosolic in the absence of ligand and that it accumulates in the nucleus in response to RA, but not upon treatment with stearic acid. Hence, like known PPARb/d ligands, RA activates the nuclear localization of FABP5. The effects of FABP5 on the ability of RA to activate PPARb/d were examined by transactivation assay using COS-7 cells, which express very low level of either FABP5 or CRABP-II. Cells were cotransfected with a luciferase reporter construct driven by a PPRE, an expression vector for PPARb/d, and a vector harboring cDNA for either FABP5 or CRABP-II. Cells were then treated with RA, and the expression of the reporter monitored ( Figure 3D , left panel). RA enhanced the expression of the PPREdriven reporter in a dose-responsive manner. While expression of CRABP-II did not affect the activity, FABP5 significantly enhanced RA-induced, PPARb/d-mediated transactivation. To investigate the effect of the binding proteins on RA-induced activation of RAR, cells were transfected with a luciferase reporter under the control of an RAR response element (RARE), an expression construct for RARa, and a vector harboring cDNA for either FABP5 or CRABP-II. In agreement with previous reports, CRABP-II augmented RA-induced transactivation of RAR. On the other hand, FABP5 had little effect on this activity ( Figure 3D, right panel) . Cells in which the receptors were not ectopically expressed displayed qualitatively similar behaviour, but the magnitudes of the ligandinduced responses were significantly smaller (not shown).
The involvement of FABP5 in RA-induced activation of PPARb/d was further investigated by examining the effect of decreasing the expression level of this binding protein on the ability of RA to activate the receptor in HaCaT cells. Cells were transfected with FABP5 siRNA, resulting in an about 80% decrease in the level of the protein, and induction of the PPARb/d target gene ADRP was monitored ( Figure 3E ). Decreasing the expression of FABP5 markedly attenuated the ability of both GW0742 and RA to Decreasing the FABP5/CRABP-II Ratio in HaCaT and NaF Cells Converts RA from a Survival Factor to a Proapoptotic Agent The observations that RA is delivered to RAR by CRABP-II and is shuttled to PPARb/d by FABP5 suggest that differential expression profiles of these iLBPs may regulate the partitioning of RA between the two receptors in different cells. The levels of the two binding proteins were thus examined in several tissues and cells. Of special interest are mammary tumors that arise in the transgenic mouse cancer model MMTVneu. RA treatment of MMTVneu mice facilitates mammary tumor development (Figure 1 ). On the other hand, it was previously reported that ectopic expression of CRABP-II in these tumors induces carcinoma cell apoptosis and suppresses tumor growth (Manor et al., 2003) , indicating that, under these conditions, RA exerts growth-inhibitory activities. Comparison between the expression levels of CRABP-II and FABP5 in tumors that arise in MMTVneu mice and in adjacent normal mammary tissue revealed that CRABP-II expression is markedly decreased, while the level of FABP5 is significantly higher in the tumors ( Figure 4A ). Hence, tumor development in MMTVneu mice is accompanied by a dramatic decrease in the CRABP-II/FABP5 ratio. Corresponding to this expression profile in vivo, NaF cells, a cell line derived from MMTVneu tumors, display a high level of FABP5 and minimal expression of CRABP-II ( Figure 4B ). Similarly, HaCaT cells, in which RA can function through PPARb/d, express a high level of FABP5 and an undetectable CRABP-II content ( Figure 4B ). In contrast, the mammary carcinoma MCF-7 cells, in which RA activates RAR to inhibit cell growth (Donato and Noy, 2005; Donato et al., 2007; Mangiarotti et al., 1998; Toma et al., 1998) , and F9 teratocarcinoma cells, which differentiate into primitive endoderm in response to RA-induced, RAR-mediated signaling (Rochette-Egly and Chambon, 2001; Strickland and Mahdavi, 1978; Strickland et al., 1980) , express a markedly higher CRABP-II/FABP5 ratio ( Figure 4B ).
The effect of reversing the CRABP-II/FABP5 ratio in HaCaT cells on the ability of RA to activate PPARb/d was then examined. Cells were transfected with either an expression vector for CRABP-II, or with a construct harboring FABP5 siRNA ( Figure 4C ), treated with RA or GW0742, and induction of the PPARb/d target gene PDK-1 was monitored ( Figure 4D ). Overexpression of CRABP-II had little effect on GW0742-induced expression of PDK-1 mRNA, indicating that this protein does not directly affect PPARb/d activity. Either overexpression of CRABP-II or underexpression of FABP5 abolished the ability of RA to induce PDK-1 expression. Additionally, in accordance with the observations that GW0742 tightly binds to FABP5 and mobilizes it to the nucleus (Figure 3) , decreasing FABP5 expression augmented the transcriptional activity of this ligand. The data thus show that increasing the CRABP-II/FABP5 ratio in HaCaT cells diverts RA away from PPARb/d. The involvement of FABP5 in induction of PDK-1 by both RA and GW0742 also supports the notion that this binding protein mediates the nuclear targeting of both of these PPARb/d ligands.
Upregulation of PDK-1 expression upon activation of PPARb/d by RA in HaCaT cells results in the phosphorylation and thus the activation of the survival factor Akt (Figure 2E) . It can thus be predicted that RA treatment will protect these cells against apoptosis. To examine this notion, HaCaT cells were treated with the apoptosis inducer tumor necrosis factor a (TNFa), and the effects of RA, the PPARb/ d ligand GW0742, and the RAR ligand TTNPB on TNFainduced apoptosis were examined. To this end, we monitored the ability of TNFa to trigger the cleavage of poly-(ADP-ribose) polymerases (PARP), one of the earliest proteins targeted for a specific cleavage during apoptosis ( Figures 5A and 5B) . TNFa treatment significantly enhanced PARP cleavage, demonstrating the efficacy of the cytokine as an apoptosis-inducing agent in these cells. In agreement with a role for PPARb/d in enabling keratinocyte survival during inflammation (Di-Poi et al., 2002; Tan et al., 2001) , activation of the receptor by GW0742 inhibited TNFainduced apoptosis. Similarly to GW0742, RA protected the cells from TNFa-induced apoptosis. In contrast, the RAR-ligand TTNPB induced apoptosis when administered alone and augmented TNFa-induced PARP cleavage, demonstrating that RAR displays proapoptotic activities in these cells. Hence, in HaCaT cells, RA inhibits apoptosis like a bona-fide PPARb/d ligand, an activity that diametrically contrasts with the proapoptotic activities of RAR.
The hypothesis that CRABP-II and FABP5 control the partitioning of RA between RAR and PPARb/d and thus the biological activities of this hormone was further investigated by examining the outcome of changing the CRABP-II/FABP5 ratio on the ability of RA to modulate TNFa-induced apoptosis. In these experiments, apoptosis was followed by monitoring the transfer of phosphatidylserine to the outer leaflet of the cell membrane, a process linked to the execution phase of apoptosis. In agreement with observations obtained by monitoring PARP cleavage as a ''readout'' for apoptosis, treatment of HaCaT cells with GW0742 or RA had little effect, while the RAR-ligand TTNPB increased the fraction of apoptotic cells ( Figure 5C ). Also in agreement, TNFa efficiently induced apoptosis, both GW0742 and RA inhibited, and TTNPB enhanced the response. Strikingly, overexpression of CRABP-II not only abolished the protective activity of RA but converted it into an agent that, similarly to TTNPB, enhanced TNFa-induced apoptosis. Reduced expression of FABP5 also negated the antiapoptotic activity of RA. The observation that the decreased expression of FABP5 did not quite lead to an enhancement of the apoptotic response likely reflects that transfection of FABP5 siRNA reduced but did not completely inhibit the expression of the protein ( Figure 4C ). Similar effects were observed in NaF cells, derived from mammary tumors of the MMTVneu mouse model; RA ''rescued'' NaF cells from TNFa-induced apoptosis, and either overexpression of CRABP-II or underexpression of FABP5 abolished the protective activity of RA and enhanced the apoptotic response ( Figure 5D ). In MCF-7 Cells, Increasing the FABP5/CRABP-II Ratio Converts RA from a Proapoptotic to an Antiapoptotic Agent Unlike HaCaT and NaF cells, the mammary carcinoma MCF-7 cells display a high CRABP-II/FABP5 ratio (Figure 4B) . To reverse this ratio, cells were cotransfected with an expression vector for FABP5 and a construct harboring CRABP-II siRNA ( Figure 6A ). The ensuing concomitant increase in FABP5 and decrease in CRABP-II levels did not affect the expression of either RAR or PPARb/d (Figure S2) . Nevertheless, the reversal hampered the ability of RA to upregulate the expression of the cell-cycle regulator BTG2, a gene that was recently shown to comprise a direct target for RAR and to be involved in mediating RA-induced cell cycle arrest in MCF-7 cells (Donato et al., 2007) (Figure 6B) . Correspondingly, the reversal abolished the ability of RA to downregulate the expression of cyclin D1, a known downstream target for BTG2 (Guardavaccaro et al., 2000; Kawakubo et al., 2006; Kawakubo et al., 2004; Lim et al., 1989) (Figure 6C ). Reversing the FABP5/CRABP-II also inhibited RA-induced induction of the RAR target cyp26a ( Figure 6D ). Remarkably, while RA had little effect on the level of the direct PPARb/d target gene PDK-1 in parental MCF-7 cells, the ligand significantly upregulated the expression of this survival factor upon the reversal of the ratio of the binding proteins ( Figure 6E ). Hence, increasing the FABP5/CRABP-II ratio in MCF-7 cells directed RA away from RAR and toward PPARb/d. Considering the disparate nature of the RAR and PPARb/d target genes, the observations suggest that the reversal of the CRABP-II/FABP5 ratio hampered growth-inhibitory activities and triggered a survival response.
To further examine the consequences of the ''switch'' in binding-protein profile, parental MCF-7 cells and cells in which the CRABP-II/FABP5 ratio was reversed were treated with the apoptosis-inducing agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Apoptosis was monitored by following PARP cleavage ( Figure 6F ) as well as by monitoring transfer of phosphatidylserine to the outer leaflet of the cell membrane ( Figure 6G ). Transfection of constructs encoding FABP5 and CRABP-II siRNA resulted in PARP cleavage even in the absence of TRAIL. The effect is likely to stem from a degree of apoptosis induced by the forced overexpression and was not observed upon monitoring later apoptosis events, represented by phosphatidylserine membrane ''flip.'' Treatment with TRAIL induced marked apoptosis, as judged by both PARP cleavage and by plasma membrane events. Addition of TRAIL in conjunction with RA had little effect (PARP cleavage) or somewhat enhanced apoptosis (phosphatidylserine translocation). Remarkably, both ''read-outs'' clearly demonstrated that, in cells in which the CRABP-II/FABP5 ratio was reversed, RA treatment markedly inhibited TRAIL-induced apoptosis. Hence, increasing the FABP5/CRABP-II ratio in MCF-7 cells results in conversion of RA from a growth-inhibitory to a prosurvival factor.
DISCUSSION
RA activates the nuclear receptor RAR, and in many embryonic and adult tissues the biological activities of this hormone can be traced to induction of expression of RAR target genes. However, in some tissues, such as skin, important functions of RA appear to be mediated by an RAR-independent pathway, the nature of which remained unclear. The observations presented here indicate that, in addition to activating RAR, RA can also activate the 1 mM) , or both, and apoptosis was assessed by assessing PARP cleavage (F) and by monitoring transfer of phosphatidylserine to the plasma membrane outer leaflet using the APOPercentage Apoptosis Assay kit (G).
nuclear receptor PPARb/d and, thus, that the repertoire of genes and cellular responses that can be controlled by this hormone include both RAR and PPARb/d targets. The data show further that partitioning of RA between its two receptors is regulated by cognate iLBPs; CRABP-II delivers RA to RAR, while FABP5 shuttles the hormone to PPARb/d (Figure 7 ). It should be noted that the binding affinity of the CRABP-II/RAR pathway for RA exceeds that of the FABP5/PPARb/d path. The interactions of RA with both CRABP-II and RAR are characterized by Kds in the 0.1-0.2 nM range (Dong et al., 1999; Sussman and de Lera, 2005) , while both FABP5 and PPARb/d associate with this compound at a Kd of 10-50 nM (Figure 3A) . It can thus be predicted that, in most cells, RA signaling through RAR will predominate and that activation of PPARb/d will become apparent only in cells that exhibit a high FABP5/CRABP-II ratio. This indeed appears to be the case. In MCF-7 cells, which express a low FABP5/ CRABP-II ratio, RA activates RAR, while keratinocytes and NaF cells, which display a high FABP5/CRABP-II ratio, respond to RA by activation of PPARb/d.
A high FABP5/CRABP-II ratio abolishes RA-triggered upregulation of RAR target genes that mediate important biological responses, such as cell-cycle arrest ( Figures  6B and 6C) . It is worth noting however that cells that display such a ratio retain the ability to induce the expression of very efficient RAR targets, such as the RA-degrading enzyme Cyp26a, albeit at a muted response ( Figures 2G  and 6D ). Hence, critical functions of RA that are mediated by RAR, such as the ability to trigger its own degradation by upregulting the expression of Cyp26 (White et al., 1996) , can proceed in the background of the predominant action of RA-evoked PPARb/d signaling.
The present work demonstrates that RA serves as a physiological ligand for PPARb/d under some but not all circumstances. However, this receptor displays nearubiquitous tissue expression (Kliewer et al., 1994) , raising the question of the nature of the ligand(s) that activate it in tissues that do not support activation by RA. The ligandbinding pocket of PPARb/d is much larger than the pockets of other nuclear receptors (Xu et al., 1999) . It may thus accommodate multiple ligands, and it has been suggested that various long chain fatty acids and eicosanoids may serve as effective PPARb/d activators (Bucco et al., 1997) . Whether some of these ligands function as true physiological ligands for the receptor remains to be clarified, but the present work and the similar nature of ligands that bind to FABPs and PPARs Widstrom et al., 2001 ) raise the possibility that FABPs other than FABP5 may act to deliver ligands other than RA to PPARb/d and, thus, that they may regulate the functionality of distinct ligands in specific tissues.
When enabled, RA signaling through PPARb/d has profound functional consequences. One consequence, explored here, is that such signaling evokes potent antiapoptotic activities that overcome the growth-inhibitory activities of RAR and allow cells to survive in the face of powerful apoptotic agents. Hence, RA-dependent maintenance of skin integrity, proliferation of basal keratinocytes, and survival of these cells during wound repair likely stem from a high expression level of FABP5, enabling RA to activate PPARb/d. Activation of PPARb/d by RA also appears to underlie the facilitation of mammary tumor progression in MMTVneu mice by this hormone. In support of this conclusion are the observations that RA functions as antiapoptotic agent in cells derived from MMTVneu tumors, that a high FABP5/CRABP-II ratio is required for this activity, that tumor progression in MMTVneu mice is accompanied by marked increase in the FABP5/CRABP-II ratio, and that decreasing this ratio by ectopic overexpression of CRABP-II triggers apoptosis and inhibits tumor development in vivo (Manor et al., 2003) . It is worth noting in regard to this that it has been reported FABP5 is expressed in melanocytic tumors but not in normal human melanocytes (Brouard et al., 2002) , indicating that elevation in the expression of this protein and thus activation of PPARb/d accompanies tumorigenesis in various cancers. While not directly addressed here, the observations that RA is critical for neuronal survival (Henion and Weston, 1994; Jacobs et al., 2006; Plum et al., 2001; Rodriguez-Tebar and Rohrer, 1991; Wuarin et al., 1990) raise the possibility that the brain may comprise another organ in which RA signals through PPARb/d. It is interesting to note regarding this possibility that the expression level FABP5 is high during neurogenesis in the developing rat brain , that this protein is required for neuronal outgrowth in PC12 neuronal cells (Allen et al., 2000) , and that its expression is induced following nerve injury (De Leon et al., 1996) , suggesting an involvement in survival/repair processes.
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